Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 43

929 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
929
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

929 trials in Villejuif

Open in trial search

Malignant melanoma

Not recruiting

A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Malignant melanoma

Not recruiting

Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Non-small cell lung cancer

Not recruiting

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Neuroendocrine carcinoma

Not recruiting

Study of Tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:S095035
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Zelenectide Pevedotin in Adults with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer with NECTIN4 Amplification

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ZELENECTIDE PEVEDOTIN
  • Sponsor:Bicycletx Limited

Prostate cancer metastatic

Not recruiting

Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer

Not recruiting

Evaluation of COM701 as Maintenance Therapy for Patients with Relapsed Platinum-Sensitive Ovarian Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Compugen Ltd.

Squamous cell carcinoma of head and neck

Not recruiting

Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:PUCOTENLIMAB
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.